Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

Summary

Sorafenib may stop the growth of cancer cells by blocking blood flow to the cancer and by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well sorafenib works in treating patients with chemosensitive recurrent aggressive non-Hodgkin's lymphoma

Timeline

Start

2005-10

Primary completion

2007-12

Completion

—

Drugs

Indications